<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01278797</url>
  </required_header>
  <id_info>
    <org_study_id>1235.41</org_study_id>
    <nct_id>NCT01278797</nct_id>
  </id_info>
  <brief_title>Telmisartan and Amlodipine Versus Monocomponent Tablets</brief_title>
  <official_title>A Single-Dose, Comparative Bioavailability Study of Telmisartan/Amlodipine 80 mg/10 mg Tablets Versus Micardis 80 mg Tablets With Norvasc 10 mg Tablets Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This study will be an open-label, randomized, two-treatment, two-period, two-sequence
      crossover study to evaluate the bioequivalence of the amlodipine component of Boehringer
      Ingelheim Pharma GmbH &amp; Co. KGs 80 mg telmisartan/10 mg amlodipine fixed dose combination
      tablet to the corresponding mono-component amlodipine tablets, 10 mg (Pfizers Norvasc).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72)</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>Area under the analyte concentration versus time curve from time zero to 72 hours as calculated by the linear trapezoidal method</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of Amlodipine</measure>
    <time_frame>Day 1, Day 22</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Concentration of Amlodipine (TMAX)</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>Time of maximum measured amlodipine concentration over the zero to 72 hour sampling period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan/Amlodipine Fixed Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Telmisartan/Amlodipine medium fixed dose combination tablet once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amlodipine Monocomponent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amlodipine Monocomponent 10mg tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan/Amlodipine Combination Tablet</intervention_name>
    <description>Combination Tablet</description>
    <arm_group_label>Telmisartan/Amlodipine Fixed Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine Monocomponent</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Amlodipine Monocomponent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy, non-smoking, male and/or post-menopausal/surgically sterile female subjects
             from 18 to 55 years of age.

          2. Females who participate in this study must either:

               1. be post-menopausal for at least 1 year (no menstrual cycle for 12 consecutive
                  months) and deemed post-menopausal by a physician based on screening clinical
                  laboratory tests (Follicle stimulating hormone (FSH) and Luteinising Hormone (LH)

               2. provide proof of surgical sterility.

          3. Body Mass Index (BMI) greater than or equal to 19.0 and less than or equal to 30.0
             kg/m2.

          4. No clinically significant findings in vital signs measurements and systolic blood
             pressure greater than or equal to 110 mmHg at screening.

          5. No clinically significant abnormal laboratory values.

          6. No clinically significant findings in a 12-lead electrocardiogram (ECG) and the time
             between the P and the R waves on the ECG (PR interval) less than or equal to 200 ms at
             screening.

          7. Have no significant diseases.

          8. Be informed of the nature of the study and give written consent prior to receiving any
             study procedure.

          9. Have no clinically significant findings from a physical examination.

        Exclusion criteria:

          1. Known history or presence of any clinically significant medical condition.

          2. Known or suspected carcinoma.

          3. History or presence of cardiovascular dysfunction (e.g. increased angina, myocardial
             infarction, outflow obstruction, congestive heart failure).

          4. History of clinically significant hypotension.

          5. Presence of hepatic dysfunction.

          6. Known history or presence of galactose or fructose intolerance, sucrase-isomaltase
             insufficiency, Lapp lactase insufficiency, galactosemia, or glucose-galactose
             malabsorption syndrome.

          7. History of gastrointestinal tract surgery (appendectomy is permitted).

          8. Presence of clinically significant gastrointestinal disease or history of
             malabsorption within the last year.

          9. Presence of a medical condition requiring regular medication (prescription and/or
             over-the-counter) with systemic absorption.

         10. History of drug or alcohol addiction requiring treatment.

         11. Positive test result for serum hCG consistent with pregnancy (females only), HIV,
             Hepatitis B surface antigen, or Hepatitis C antibody.

         12. Positive test result for urine drugs of abuse (cannabinoids, opiates, amphetamines,
             cocaine, phencyclidine, tricyclic antidepressants, barbiturates, methadone, and
             benzodiazepines) or urine cotinine.

         13. Difficulty fasting or consuming standard meals.

         14. Females who are pregnant, lactating, or likely to become pregnant during the study.

         15. Does not tolerate venipuncture.

         16. Use of tobacco or nicotine-containing products within 6 months prior to drug
             administration.

         17. On a special diet within 30 days prior to drug administration (e.g. liquid, protein,
             raw food diet).

         18. Participated in another clinical trial or received an investigational product within
             30 days prior to drug administration.

         19. Donation or loss of whole blood:

               1. Great than or equal to 50 mL and less than or equal to 499 mL within 30 days
                  prior to dosing

               2. greater than or equal to 500 mL within 56 days prior to dosing.

         20. Females who have used hormonal contraceptives within 6 months prior to drug
             administration.

         21. Have had a tattoo or body piercing within 30 days prior to dosing.

         22. Known history or presence of hypersensitivity or idiosyncratic reaction to
             telmisartan, amlodipine, or any other drug substances with similar activity.

         23. Use of any drugs known to:

               1. induce (e.g. barbiturates, carbamazepine, phenytoin, glucocorticoids, omeprazole)

               2. inhibit (e.g. antidepressants (Selective Seratonin Reuptake Inhibitor (SSRI)I),
                  cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil,
                  fluoroquinolones, antihistamines) hepatic drug metabolism within 30 days prior to
                  drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.41.0001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2011</study_first_submitted>
  <study_first_submitted_qc>January 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2011</study_first_posted>
  <results_first_submitted>February 13, 2012</results_first_submitted>
  <results_first_submitted_qc>February 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 16, 2012</results_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telm/Amlo 80 mg/10 mg First, Then Telm 80 mg + Amlo 10 mg</title>
          <description>Combination tablet followed by individual components</description>
        </group>
        <group group_id="P2">
          <title>Telm 80 mg + Amlo 10 mg First, Then Telm/Amlo 80 mg/10 mg</title>
          <description>Individual components followed by Combination tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period of 21 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes all subjects randomized to either treatment sequence</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic/Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.1" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.3" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilogram / square meter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72)</title>
        <description>Area under the analyte concentration versus time curve from time zero to 72 hours as calculated by the linear trapezoidal method</description>
        <time_frame>Day 1, Day 22</time_frame>
        <population>Analysis Set includes all randomized participants who completed the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Telm/Amlo 80 mg/10 mg</title>
            <description>Combination tablet</description>
          </group>
          <group group_id="O2">
            <title>Telm 80 mg + Amlo 10 mg</title>
            <description>Individual tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve of Plasma Amlodipine From 0 to 72 Hours (AUC72)</title>
          <description>Area under the analyte concentration versus time curve from time zero to 72 hours as calculated by the linear trapezoidal method</description>
          <population>Analysis Set includes all randomized participants who completed the trial</population>
          <units>nanograms*hour/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.7971" spread="60.8717"/>
                    <measurement group_id="O2" value="276.6315" spread="66.1935"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Telmisartan/Amlodipine 80 mg/10 mg versus Telmisartan 80 mg + Amlodipine 10 mg The two formulations are shown to be bioequivalent since the 90% confidence interval of the test to reference ratio is entirely contained within the 80-125% bioequivalence range.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA was applied to log-transformed AUC72 and Included treatment, sequence, period and subject-within-sequence effects.</method_desc>
            <param_type>Test/Reference ratio of geometric means</param_type>
            <param_value>94.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>91.60</ci_lower_limit>
            <ci_upper_limit>97.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) of Amlodipine</title>
        <time_frame>Day 1, Day 22</time_frame>
        <population>Analysis Set includes all randomized participants who completed the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Telm/Amlo 80 mg/10 mg</title>
            <description>Combination tablet</description>
          </group>
          <group group_id="O2">
            <title>Telm 80 mg + Amlo 10 mg</title>
            <description>Individual tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) of Amlodipine</title>
          <population>Analysis Set includes all randomized participants who completed the trial</population>
          <units>nanograms/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7465" spread="1.3354"/>
                    <measurement group_id="O2" value="7.2258" spread="1.6549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Telmisartan/Amlodipine 80 mg/10 mg versus Telmisartan 80 mg + Amlodipine 10 mg The two formulations are shown to be bioequivalent since the 90% confidence interval of the test to reference ratio is entirely contained within the 80-125% bioequivalence range.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA was applied to log-transformed CMAX and Included treatment, sequence, period and subject-within-sequence effects.</method_desc>
            <param_type>Test/Reference ratio of geometric means</param_type>
            <param_value>94.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>90.70</ci_lower_limit>
            <ci_upper_limit>97.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Maximum Concentration of Amlodipine (TMAX)</title>
        <description>Time of maximum measured amlodipine concentration over the zero to 72 hour sampling period</description>
        <time_frame>Day 1, Day 22</time_frame>
        <population>Analysis Set includes all randomized participants who completed the trial</population>
        <group_list>
          <group group_id="O1">
            <title>Telm/Amlo 80 mg/10 mg</title>
            <description>Combination tablet</description>
          </group>
          <group group_id="O2">
            <title>Telm 80 mg + Amlo 10 mg</title>
            <description>Individual tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Concentration of Amlodipine (TMAX)</title>
          <description>Time of maximum measured amlodipine concentration over the zero to 72 hour sampling period</description>
          <population>Analysis Set includes all randomized participants who completed the trial</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.69" spread="1.95"/>
                    <measurement group_id="O2" value="6.12" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Telmisartan/Amlodipine 80 mg/10 mg versus Telmisartan 80 mg + Amlodipine 10 mg</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>ANOVA</method>
            <method_desc>ANOVA was applied to TMAX and Included treatment, sequence, period and subject-within-sequence effects.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.58</param_value>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telm/Amlo 80 mg/10 mg</title>
          <description>Combination tablet</description>
        </group>
        <group group_id="E2">
          <title>Telm 80 mg + Amlo 10 mg</title>
          <description>Individual tablets</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

